Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01575873
Other study ID # 20101217
Secondary ID 2010-024393-19
Status Completed
Phase Phase 3
First received
Last updated
Start date March 28, 2012
Est. completion date June 29, 2017

Study information

Verified date July 2018
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.


Recruitment information / eligibility

Status Completed
Enrollment 795
Est. completion date June 29, 2017
Est. primary completion date June 21, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Men and women 18 years of age or older who have been taking glucocorticoid treatment. Men and women who are less than 50 years of age must have had a fracture as an adult to be eligible. Men and women who are 50 years of age or older who have been taking glucocorticoids must meet protocol-specific BMD criteria.

Exclusion Criteria:

Use of agents affecting bone metabolism, use of more than one biologic agent for inflammatory disease, history of bone disease (except osteoporosis), low vitamin D level (one can enter the trial after vitamin D levels are corrected), abnormalities of blood calcium, an underactive or overactive thyroid condition that is not treated and stable, Addison's disease, any abnormality of the parathyroid glands (the glands that control blood calcium), currently pregnant or planning a pregnancy, currently breast feeding, and other criteria may apply.

Study Design


Related Conditions & MeSH terms

  • Steroid-induced Osteopor, Glucocorticoid-induced Ostepor

Intervention

Drug:
Denosumab
Administered by subcutaneous injection once every 6 months
Placebo for risendronate
Administered orally once a day
Risendronate
Administered orally once a day
Placebo for denosumab
Administered by subcutaneous injection once every 6 months

Locations

Country Name City State
Argentina Research Site Buenos Aires
Argentina Research Site Ciudad Autonoma de Buenos Aires Buenos Aires
Argentina Research Site Ciudad Autonoma de Buenos Aires Buenos Aires
Belgium Research Site Bruxelles
Belgium Research Site Genk
Belgium Research Site Gent
Belgium Research Site Liege
Belgium Research Site Wilrijk
Canada Research Site Barrie Ontario
Canada Research Site Hamilton Ontario
Canada Research Site Montreal Quebec
Canada Research Site Montreal Quebec
Canada Research Site Quebec
Canada Research Site Saskatoon Saskatchewan
Canada Research Site Trois-Rivieres Quebec
Canada Research Site Vancouver British Columbia
Canada Research Site Waterloo Ontario
Canada Research Site Westmout Quebec
Colombia Research Site Barranquilla Atlántico
Czechia Research Site Brno
Czechia Research Site Pardubice
Czechia Research Site Plzen
Czechia Research Site Praha 11 - Chodov
Czechia Research Site Praha 2
Czechia Research Site Praha 3
Czechia Research Site Uherske Hradiste
Denmark Research Site Aalborg
Denmark Research Site Århus C
Denmark Research Site Ballerup
Denmark Research Site Vejle
France Research Site Lyon Cédex 3
France Research Site Orleans Cedex
France Research Site Vandoeuvre les Nancy
Germany Research Site Bad Nauheim
Germany Research Site Bad Reichenhall
Germany Research Site Berlin
Germany Research Site Hildesheim
Germany Research Site Köln
Germany Research Site Vogelsang-Gommern
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Debrecen
Hungary Research Site Gyula
Hungary Research Site Szeged
Hungary Research Site Szikszo
Korea, Republic of Research Site Daegu
Korea, Republic of Research Site Daejeon
Korea, Republic of Research Site Gwangju
Korea, Republic of Research Site Jinju-si
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Mexico Research Site Leon Guanajuato
Mexico Research Site Mexico Distrito Federal
Mexico Research Site Morelia Michoacán
Mexico Research Site San Luis Potosi San Luis Potosí
Netherlands Research Site Amsterdam
Netherlands Research Site Helmond
Netherlands Research Site Utrecht
Poland Research Site Bialystok
Poland Research Site Kraków
Poland Research Site Lodz
Poland Research Site Poznan
Poland Research Site Poznan
Poland Research Site Stalowa Wola
Poland Research Site Torun
Poland Research Site Warszawa
Poland Research Site Warszawa
Poland Research Site Wroclaw
Russian Federation Research Site Ekaterinburg
Russian Federation Research Site Moscow
Russian Federation Research Site Moscow
Russian Federation Research Site Nizhniy Novgorod
Russian Federation Research Site Saint Petersburg
Russian Federation Research Site Saint Petersburg
Russian Federation Research Site Saint-Petersburg
Russian Federation Research Site Yaroslavl
Spain Research Site Barcelona Cataluña
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Valencia Comunidad Valenciana
United States Research Site Beckley West Virginia
United States Research Site Bethesda Maryland
United States Research Site Birmingham Alabama
United States Research Site Boston Massachusetts
United States Research Site Chicago Illinois
United States Research Site Cumberland Maryland
United States Research Site Detroit Michigan
United States Research Site Duncansville Pennsylvania
United States Research Site Evanston Illinois
United States Research Site Fargo North Dakota
United States Research Site Fargo North Dakota
United States Research Site Gainesville Georgia
United States Research Site Indianapolis Indiana
United States Research Site Lakewood Colorado
United States Research Site Mayfield Ohio
United States Research Site Pembroke Pines Florida
United States Research Site Sacramento California
United States Research Site Wyomissing Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Countries where clinical trial is conducted

United States,  Argentina,  Belgium,  Canada,  Colombia,  Czechia,  Denmark,  France,  Germany,  Hungary,  Korea, Republic of,  Mexico,  Netherlands,  Poland,  Russian Federation,  Spain, 

References & Publications (1)

Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018 Jun;6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5. Epub 2018 Apr 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis) Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). Baseline and month 12
Secondary Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Superiority Analysis) Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). Baseline and month 12
Secondary Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12 Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA). Baseline and month 12
Secondary Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 24 Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). Baseline and month 24
Secondary Percent Change From Baseline in Total Hip Bone Mineral Density at Month 24 Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA). Baseline and month 24